The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and the Wuhan Institute of Virology at the Chinese Academy of Sciences have divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Rakovina Therapeutics Inc. has described dual NAD+ ADP-ribosyltransferase (poly(ADP-ribose) polymerase; PARP) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of Ewing sarcoma.
Merck Sharp & Dohme LLC has disclosed diacylglycerol acyltransferase type 2 (DGAT2) inhibitors reported to be useful for the treatment of atherosclerosis, type 2 diabetes, fibrosis, heart failure, hepatic steatosis, hypercholesterolemia, hyperlipidemia and obesity, among others.
Bristol Myers Squibb Co. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) targeting moiety through a linker reported to be useful for the treatment of cancer.
Biosplice Therapeutics Inc. has disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and Alzheimer’s disease.
Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections.
Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuven ) have jointly developed new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19), rhinovirus and norovirus infections.
RSS